Endologix's CEO Presents At Morgan Stanley Healthcare Conference (Transcript)

Endologix Inc. (ELX)

Morgan Stanley Healthcare Conference

September 10, 2012 11:45 am ET

Executives

John McDermott - Chairman of the Board, President, Chief Executive Officer

Analysts

Presentation

Unidentified Analyst

Compare to:
Previous Statements by ELGX
» Endologix's CEO Discusses Q2 2012 Results - Earnings Call Transcript
» Endologix's CEO Presents at the 2012 Bank of America Merrill Lynch Health Care Conference (Transcript)
» Endologix's CEO Discusses Q1 2012 Results - Earnings Call Transcript
» Endologix's CEO Discusses Q4 2011 Results - Earnings Call Transcript

Great, let's go ahead and get started here. I look managed care with medical devices. So it’s a pleasure to have with us here the session before we get into the lunch break here, Endologix's CEO, John McDermott. Just quickly for medical device recent disclosures, go to the Morgan Stanley website and you can see all of my recent disclosures. It’s a great read.

So, for many of you know this, that Endologix is not a covered company for Morgan Stanley. So the real question is, why are they here and the route is, we see Endologix is attacking a very large and growing end-market in AAA stenting and John will sort of walk us through that.

I also would say this, since John has joined the company, several years ago, you have seen significant improvement in both their international distribution, their product reps have expanded the business in terms of the pipeline with their acquisition of Nellix. So this business in the last three to four years has been completely transformed and John obviously has a lot to with that.

So we see here is an emerging medical device company in an important growing end market and frankly with a significant amount of operational change. So what we are going to do is let John and he will give us a minute preamble and then we are going to jump into the Q&A. John.

1 2 3 4 Next › Last »